14132-18-4

Basic information

• Product Name: 6a,7,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
• Synonyms: 6a,7,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
• CAS NO: 14132-18-4
• Molecular Formula: C21H30O2
• Molecular Weight: 314.46
• Mol File: 14132-18-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6a,7,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 6a,7,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol(14132-18-4)
• EPA Substance Registry System: 6a,7,10,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol(14132-18-4)

Safety Data

• Hazardous Substances Data: 14132-18-4(Hazardous Substances Data)

Upstream product

• 500-66-3 Olivetol 
• 38862-65-6 2,4-dihydroxy-6-n-pentylbenzoic acid ethyl ester 
• 945-51-7 1,1'-sulfinylbisbenzene 
• 139-66-2 diphenyl sulfide 
• 22771-44-4 (+)-p-mentha-2,8-dien-1-ol 
• 31684-93-2 (+)-limonene oxide 
• 3556-78-3 cannabidiol 

Relevant articles and documents

Process for production of delta-9- tetrahydrocannabinol

The present invention relates to a process for preparation of a delta-9-tetrahydrocannabinol compound or derivative thereof involving treating a first intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the delta-9-tetrahydrocannabinol compound or derivative thereof. Another aspect of the present invention relates to a process for preparation of a cannabidiol or cannabidiolate compound involving reacting a first starting compound with a second starting compound in the presence of a metal triflate catalyst, under conditions effective to form the cannabidiol or cannabidiolate compound. The present invention also relates to a compound of the formula: where R8, R9, and R10 are the same or different and independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or halo, with R1, R2, and R3 defined herein.

CANNABINOID ACTIVE PHARMACEUTICAL INGREDIENT FOR IMPROVED DOSAGE FORMS

Pharmaceutical compositions comprising the cannabinoid active pharmaceutical ingredient, crystalline trans-(±)-Δ9-tetrahydrocannabinol, and formulations thereof are disclosed. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of crystalline trans-(±)-Δ9-tetrahydrocannabinol. In specific embodiments, the crystalline trans-(±)-Δ9-tetrahydrocannabinol administered according to the methods for treating or preventing a condition such as pain can have a purity of at least about 98% based on the total weight of cannabinoids.